J&J results beat estimates but Remicade concerns prevail

23 January 2018

US healthcare giant Johnson & Johnson (NYSE: JNJ) slipped by 2.5% in the stock market in the two hours after it reported its fourth quarter and annual financial results for 2017.

This is despite J&J exceeding Wall Street estimates with its quarterly results overall, with the revenue total of $20.2 billion above the $20.1 billion expected, according to Thomson Reuters. Adjusted earnings per share (EPS) were $0.02 higher than anticipated, at $1.74, on adjusted net income of $4.78 billion, up about 10% from a year ago.

"The passage of legislation modernizing the US tax system enables J&J to invest in innovation at higher levels"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK